BACKGROUND/AIM: The management of patients with clear cell renal cell carcinoma (ccRCC) includes prognosis assessment based on TNM classification and biochemical markers. This approach stratifies patients with advanced ccRCC into groups of favorable, intermediate, and poor prognosis. The aim of the study was to improve prognosis estimation using microRNAs involved in the pathogenesis of ccRCC. PATIENTS AND METHODS: The study was based on a histologically-verified set of matched ccRCC FFPE tissue samples (normal renal tissue, primary tumor, metastasis, n=20+20+20). The expression of 2,549 microRNAs was analyzed using the SurePrint G3 Human miRNA microarray kit (Agilent Technologies). Prognostic value of significantly deregulated microRNAs was further evaluated on microRNA expression and clinical data of 475 patients obtained from TCGA Kidney Clear Cell Carcinoma (KIRC) database. RESULTS: There were 13 up-regulated and 6 down-regulated microRNAs in tumor tissues compared to control tissues. Among them, survival analysis revealed those with prognostic significance. Patients with high expression of miR-21, miR-27a, miR-34a, miR-106b, miR-210, and miR-342 showed significantly unfavorable outcome. The opposite was observed for miR-30e, patients with low expression had significantly shorter survival. CONCLUSION: The inclusion of these microRNAs in a prognostic panel holds the potential to enhance stratification scoring systems, on which the treatment of ccRCC patients is based.

Biomedical Center Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Biology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Histology and Embryology Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Medical Chemistry and Biochemistry Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic

Department of Medical Chemistry and Biochemistry Faculty of Medicine in Pilsen Charles University Pilsen Czech Republic;

Department of Pathology University Hospital in Pilsen Pilsen Czech Republic

Department of Urology University Hospital in Pilsen Pilsen Czech Republic

Laboratory of Immunoanalysis University Hospital in Pilsen Pilsen Czech Republic

See more in PubMed

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. PubMed DOI

Motzer RJ, Jonasch E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(1):71–90. doi: 10.6004/jnccn.2022.0001. PubMed DOI PMC

Espana-Agusti J, Warren A, Chew SK, Adams DJ, Matakidou A. Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis. Nat Commun. 2017;8(1):2026. doi: 10.1038/s41467-017-02245-1. PubMed DOI PMC

Sanchez DJ, Simon MC. Genetic and metabolic hallmarks of clear cell renal cell carcinoma. Biochim Biophys Acta Rev Cancer. 2018;1870(1):23–31. doi: 10.1016/j.bbcan.2018.06.003. PubMed DOI PMC

Catalano M, Procopio G, Sepe P, Santoni M, Sessa F, Villari D, Nesi G, Roviello G. Tyrosine kinase and immune checkpoints inhibitors in favorable risk metastatic renal cell carcinoma: Trick or treat. Pharmacol Ther. 2023;249:108499. doi: 10.1016/j.pharmthera.2023.108499. PubMed DOI

Brierley J. Hoboken, NJ, USA, Wiley-Blackwell, 2020. TNM atlas: illustrated guide to the TNM classification of malignant tumours. Seventh edition.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer Oxf Engl 1990. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026. PubMed DOI

Smid D, Kulda V, Srbecka K, Kubackova D, Dolezal J, Daum O, Kucera R, Topolcan O, Treska V, Skalicky T, Pesta M. Tissue microRNAs as predictive markers for gastric cancer patients undergoing palliative chemotherapy. Int J Oncol. 2016;48(6):2693–2703. doi: 10.3892/ijo.2016.3484. PubMed DOI

Kiss I. Brno, Masaryk Memorial Cancer Institute, 2022. Modrá kniha České onkologické společnosti.

Graham J, Heng DYC, Brugarolas J, Vaishampayan U. Personalized management of advanced kidney cancer. Am Soc Clin Oncol Educ Book. 2018;38:330–341. doi: 10.1200/EDBK_201215. PubMed DOI PMC

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–720. doi: 10.1093/annonc/mdz056. PubMed DOI

Cheng T, Wang L, Li Y, Huang C, Zeng L, Yang J. Differential microRNA expression in renal cell carcinoma. Oncol Lett. 2013;6(3):769–776. doi: 10.3892/ol.2013.1460. PubMed DOI PMC

Goujon M, Woszczyk J, Gaudelot K, Swierczewski T, Fellah S, Gibier JB, Van Seuningen I, Larrue R, Cauffiez C, Gnemmi V, Aubert S, Pottier N, Perrais M. A double-negative feedback interaction between miR-21 and PPAR-α in clear renal cell carcinoma. Cancers (Basel) 2022;14(3):795. doi: 10.3390/cancers14030795. PubMed DOI PMC

Wang C, Xu H, Liao X, Wang W, Wu W, Li W, Niu L, Li Z, Li A, Sun Y, Huang W, Song F. Hypertension promotes the proliferation and migration of ccRCC cells by downregulation of TIMP3 in tumor endothelial cells through the miR-21–5p/TGFBR2/P38/EGR1 axis. Mol Cancer Res MCR. 2023;21(1):62–75. doi: 10.1158/1541-7786.MCR-22-0089. PubMed DOI

Wang J, Jin J, Liang Y, Zhang Y, Wu N, Fan M, Zeng F, Deng F. miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma. Front Genet. 2022;13:978840. doi: 10.3389/fgene.2022.978840. PubMed DOI PMC

Tan C, Du H, Wang Y, Zhao J, Cheng X, Lan H. LncRNA GABPB1 IT1 inhibits the tumorigenesis of renal cancer via the miR-21/PTEN axis. J Biochem Mol Toxicol. 2023;37(4):e23288. doi: 10.1002/jbt.23288. PubMed DOI

Cao J, Liu J, Xu R, Zhu X, Liu L, Zhao X. MicroRNA-21 stimulates epithelial-to-mesenchymal transition and tumorigenesis in clear cell renal cells. Mol Med Rep. 2016;13(1):75–82. doi: 10.3892/mmr.2015.4568. PubMed DOI PMC

Valera VA, Walter BA, Linehan WM, Merino MJ. Regulatory effects of microRNA-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. J Cancer. 2011;2:515–526. doi: 10.7150/jca.2.515. PubMed DOI PMC

Yoshino H, Yonemori M, Miyamoto K, Tatarano S, Kofuji S, Nohata N, Nakagawa M, Enokida H. microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. Oncotarget. 2017;8(13):20881–20894. doi: 10.18632/oncotarget.14930. PubMed DOI PMC

Tang K, Xu H. Prognostic value of meta-signature miRNAs in renal cell carcinoma: an integrated miRNA expression profiling analysis. Sci Rep. 2015;5:10272. doi: 10.1038/srep10272. PubMed DOI PMC

Samaan S, Khella HW, Girgis A, Scorilas A, Lianidou E, Gabril M, Krylov SN, Jewett M, Bjarnason GA, El-said H, Yousef GM. miR-210 is a prognostic marker in clear cell renal cell carcinoma. J Mol Diagn JMD. 2015;17(2):136–144. doi: 10.1016/j.jmoldx.2014.10.005. PubMed DOI

Ruan L, Chen J, Ruan L, Tan A, Wang P. miR-34a inhibits tumorigenesis of NSCLC via targeting SIRT6. Int J Clin Exp Pathol. 2018;11:1135–1145. PubMed PMC

Wu G, Li Z, Wang Y, Ju X, Huang R. miR-34a inhibits cell proliferation by targeting SATB2 in hepatocellular carcinoma. Biomed Res Int. 2018;2018:2863902. doi: 10.1155/2018/2863902. PubMed DOI PMC

Jing ZF, Bi JB, Li Z, Liu X, Li J, Zhu Y, Zhang XT, Zhang Z, Li Z, Kong CZ. Inhibition of miR-34a-5p can rescue disruption of the p53-DAPK axis to suppress progression of clear cell renal cell carcinoma. Mol Oncol. 2019;13(10):2079–2097. doi: 10.1002/1878-0261.12545. PubMed DOI PMC

Martoriati A, Doumont G, Alcalay M, Bellefroid E, Pelicci PG, Marine JC. dapk1, encoding an activator of a p19ARF-p53-mediated apoptotic checkpoint, is a transcription target of p53. Oncogene. 2005;24(8):1461–1466. doi: 10.1038/sj.onc.1208256. PubMed DOI

Farag AK, Roh EJ. Death-associated protein kinase (DAPK) family modulators: Current and future therapeutic outcomes. Med Res Rev. 2019;39(1):349–385. doi: 10.1002/med.21518. PubMed DOI

Zou G, Guo L, Shen S, Song Z, Ouyang Z, Yu Y. Long non-coding RNA BRE-AS1 inhibits proliferation, migration and invasion of clear cell renal cell carcinoma by downregulating miR-106b-5p. Histol. 2023;Histopathol:18653. doi: 10.14670/HH-18-653. PubMed DOI

Xiang W, He J, Huang C, Chen L, Tao D, Wu X, Wang M, Luo G, Xiao X, Zeng F, Jiang G. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma. Oncotarget. 2015;6(6):4066–4079. doi: 10.18632/oncotarget.2926. PubMed DOI PMC

Lu J, Wei JH, Feng ZH, Chen ZH, Wang YQ, Huang Y, Fang Y, Liang YP, Cen JJ, Pan YH, Liao B, Chen WF, Chen W, Luo JH. miR-106b-5p promotes renal cell carcinoma aggressiveness and stem-cell-like phenotype by activating Wnt/β-catenin signalling. Oncotarget. 2017;8(13):21461–21471. doi: 10.18632/oncotarget.15591. PubMed DOI PMC

Zhao Y, Tao Z, Chen X. Identification of the miRNA-mRNA regulatory pathways and a miR-21-5p based nomogram model in clear cell renal cell carcinoma. PeerJ. 2020;8:e10292. doi: 10.7717/peerj.10292. PubMed DOI PMC

Guo Y, Li X, Zheng J, Fang J, Pan G, Chen Z. Identification of a novel immune-related microRNA prognostic model in clear cell renal cell carcinoma. Transl Androl Urol. 2021;10(2):888–899. doi: 10.21037/tau-20-1495. PubMed DOI PMC

Feng J, Xu B, Dai C, Wang Y, Xie G, Yang W, Zhang B, Li X, Wang J. Macrophage-derived exosomal miR-342-3p promotes the progression of renal cell carcinoma through the NEDD4L/CEP55 axis. Oncol Res. 2022;29(5):331–349. doi: 10.32604/or.2022.03554. PubMed DOI PMC

Wang D, Zhu C, Zhang Y, Zheng Y, Ma F, Su L, Shao G. MicroRNA-30e-3p inhibits cell invasion and migration in clear cell renal cell carcinoma by targeting Snail1. Oncol Lett. 2017;13(4):2053–2058. doi: 10.3892/ol.2017.5690. PubMed DOI PMC

Friedrich M, Heimer N, Stoehr C, Steven A, Wach S, Taubert H, Hartmann A, Seliger B. CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma. Sci Rep. 2020;10(1):6499. doi: 10.1038/s41598-020-63403-y. PubMed DOI PMC

Na XY, Hu XQ, Zhao Y, Hu CH, Shang XS. LncRNA DNAJC3-AS1 functions as oncogene in renal cell carcinoma via regulation of the miR-27a-3p/PRDM14 axis. Eur Rev Med Pharmacol Sci. 2021;25:1291–1301. doi: 10.26355/eurrev_202102_24833. PubMed DOI

Song EL, Xing L, Wang L, Song WT, Li DB, Wang Y, Gu YW, Liu MM, Ni WJ, Zhang P, Ma X, Zhang X, Yao J, Chen Y, An RH. LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis. Aging (Albany NY) 2019;11(15):5705–5725. doi: 10.18632/aging.102154. PubMed DOI PMC

Liu Z, Liu X, Liu S, Cao Q. Cholesterol promotes the migration and invasion of renal carcinoma cells by regulating the KLF5/miR-27a/FBXW7 pathway. Biochem Biophys Res Commun. 2018;502(1):69–75. doi: 10.1016/j.bbrc.2018.05.122. PubMed DOI